



Regd. Office:

'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India.

Phone: +91-79-2686 8100 (20 Lines)

Fax : +91-79-2686 2368 www.zyduscadila.com

CIN:L24230GJ1995PLC025878

Bombay Stock Exchange Limited

1st Floor.

P.J. Towers **Dalal Street**

Mumbai - 400 001

Kind Attn.: Mr. Sanjay Golecha /

Mr. Gopalkrishnan

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block,

Bandra-Kurla Complex, Bandra (East)

Mumbai - 400 051

Kind Attn.: Famroze Pochara

Asst. Vice President

Date: August 12, 2015

Re.: **Unaudited** financial results

Re.: Unaudited financial results for the guarter ended on June 30, 2015

We are forwarding herewith unaudited financial results for the quarter ended on June 30, 2015 reviewed by Audit Committee and taken on record by the Board of Directors on August 12, 2015 pursuant to Clause 41 of the Listing Agreement; the same may please receive in order.

Thanking you

Yours faithfully

For Cadila Healthcare Limited

Upen H. Shah

Company Secretary

Encl.: As above

dedicated/ife	Zydus
•	

Cadila Healthcare Limited

Statement of Sta						CIN : L24230GJ1995PLC025878			
Rippines in Lus	PART I								
Part		Dimon	1			Statement of Results for the Quarter Ended 30/06/2015			
Precision Prec		TOSNO	TATES					Rupees	in Lacs
Part		COMPORT	Corresponding					COMP	ANY
Precenting 30/00/2014 in Precent print P			3 months ended		Sr. No.	Particulars			3 months
	3 Months ended	Preceding 3 months ended		Previous year ended			3 Months	Preceding 3	30/06/2014 in
	30/06/2015	31/03/2015	\top	31/03/2015			30/06/2015	31/03/2015	year
225.052 205.050 205.050 1 close Selection 227.34 115.050 127.343 115.050 127.343 115.050 127.343 115.050 127.343 115.050 127.343 115.050 127.343 115.050 127.343 115.050 127.343 127.050 127.343 127.050 127.343 127.050 127.343 127.050 127.343 127.050 127.343 127.050 127.343 127.050 127.343 127.050 127.343 127.050 127.0	(Ollumanica)	(numed)	(Oridodited)	(Audited)	-	come from operations	(Unaudited)	(Audited)	(Unaudited)
Autority	242,176	229,665	205,680	865,769		oss Sales	177 343	135 600	
224,117 202,038 689,732 3 Net Sites 235,949 125,939 133,736	4,348	4,953	3,642	16,057	=:	ss: Excise Duty	2,053	1 853	1 691
	237,828	224,712	202,038	849,712	a)	t Sales	175,290	133,756	98.691
Class 205,012 205,134 Class	12,237	4,111	2,974	15,422	ь	her operating income	16,212	11,639	12,588
45.054 4.7653 189.568 2 Good materials consumed 41.012 (6.343) (9.765) 189.568 2 Goods making and standard a	250,065	228,823	205,012	865,134		tal income from operations (net)	191,502	145,395	111,279
31,147 0,0534 139,703 b	53,298	45,054	47,053	189,668		st of materials consumed	25 085	70 676)
4,012 (6,345) (2,036) (2,036) (2,036) (2,036) (3,066	26,900	31,147	40,624	139,703	ь	chases of stock-in-trade	10,900	12,666	11.537
13,486 29,013 120,822 d Employee branches exceptions 120,822 d Employee branches 120,922 d Employee branches 120,922 d Employee branches 120,922 d 120	4,604	4,012	(6,345)	(9,706)	C	anges in inventories of finished goods, work-in-progress and stock-in-trade	6,108	(536)	(5,189)
	32,301	31,408	29,013	120,852	а	ployee benefits expense	17,114	15,009	15,176
16,790 17,471 17,13288 17,13288 17,13288 17,13288 17,13289 17	7,368	7,554	6,770	28,725	Ф	preciation and amortisation expense	5,184	5,539	5,295
12,003 1,4,11 1,18,288 2 10del expenses 2,004 1,4,003 104,603 104,603 2,04,003	72,811	67,615	57,056	249,046	7	ner expenses	49,512	42,282	31,715
1,041 1,04	197,282	186,790	1/4,1/1	718,288	9	ial expenses	124,803	104,638	90,189
1,288	2,083	2,034	1,041	5,537		ont/ (LOSS) from Operations before other income, finance costs and exceptional items (1-2) Per income	66,699	40,757	21,090
1,628 1,808 6,786 6 Finance costs 1,308 6,786 6 74,559 7 1,305 7	54,866	44,067	31,882	152,383	5	ofit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	68 190	42 247	22 724
42,439 30,074 145,597	1,335	1,628	1,808	6,786	6	ance costs	745	1,386	825
1.143 1.18 1.194 8 Exceptional letters 67,45 40,861 21,870 6,155 22,970 7,075 5,244 25,942 10 Tax expense 7,075 118,511 11 Net Profit/ (Loss) from ordinary activities after tax (9-10) 24,712 118,511 11 Net Profit/ (Loss) for the period (11-12) 55,575 34,706 19 19 19 19 19 19 19 1	53,531	42,439	30,074	145,597	7	ofit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	67,445	40,861	21,899
17.11 11.73 56.20 10.861 14.853 9 Profit (Loss) from ordinary activities before tax (7-8) 17.11 11.73 56.20 10.861 14.853 9 Profit (Loss) from ordinary activities after tax (9-10) 12.87.14 14.853 9 Profit (Loss) from ordinary activities after tax (9-10) 12.87.25 11.8611 11 11.73 56.20 12.87.25 10.861 12.87.25 11.8611 11 11.73 10.861 12.87.25	211	(143)	118	1,044	8	eptional items	0	0	0
17.11 11.73 56.20 10 12 13.55.575 13.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.4706 19.55.575 19.55.575 19.4706 19.55.575 19.55.57	53,320	42,582	29,956		9	ofit/ (Loss) from ordinary activities before tax (7-8)	67,445	40,861	21,899
10,237 24,712 11,0311 11	36 001	25 507	5,244		10	expense	11,870	6,155	2,170
35,507 24,712 118,611 13 Net Profit/ (Loss) for the period (11-12) 124 0 214 14 Pre-acquisition loss transferred to Goodwill arising on consolidation 19 10,237 10,237 115,059 16 Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15) 25,575 34,706 19 10,237 10,237 10,237 117 11,73 11,	0	0	0		5 =	t Prolity (Loss) from ordinary activities after tax (9-10)	55,575	34,706	19,729
214 0 214 1 Pre-acquisition loss transferred to Goodwill arising on consolidation 55,375 34,06 19 (683) (691) (3,766) 15 Minority interest 0	36,091	35,507	24,712		13 F	rovinial) kens (net 0 lak expense) t Profit / (Lose) for the period (11-12)	0	0	0
(683) (691) (3,766) 15 Minority interest 15,059 15 Minority interest 15,059 16 Met Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15) 55,575 34,706 19 10,237 1	•	214	0	-		acquisition loss transferred to Goodwill arising on consolidation	0 0	34,700	67,/61
35,038 24,021 115,059 16 Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15) 55,575 34,706 19 10,237 10,237 10,237 10,237 17 Paid-up equilty share capital (Face Value Rs. 5/-) 19 Earnings per share (before extraordinary items) 19 Earnings per share (before extraordinary items) 17.11 11.73 56.20 56.20 56.20 10 10 10 10 10 10 10	(752)	(683)	(691)	•		ority interest	۰ (0 0	0 0
10,237 10,237 10,237 17 Paid-up equity share capital (Face Value Rs. 5/-) 414,917 18 Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year 19 i Earnings per share (before extraordinary items) (of Rs. 5/- each) (not annualised): 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 b Diluted (Rs.)	35,339	35,038	24,021				55,575	34,706	19,729
414,917 18 Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year 19 i Earnings per share (before extraordinary items) (of Rs. 5/- each) (not annualised): 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 b Diluted (Rs.)	10,237	10,237	10,237	\neg		3-up equity share capital (Face Value Rs. 5/-)	10,237	10,237	10,237
19 i Earnings per share (before extraordinary items) (of Rs. 5/- each) (not annualised): 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 b Diluted (Rs.)						erves excluding Revaluation Reserve as per balance sheet of previous accounting year			
17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 17.11 11.73 56.20 b Diluted (Rs.)					_	nings per share (before extraordinary items)			
17.11 11.73 56.20 b Diluted (Rs.) 19 ii Earnings per share (after extraordinary items) (of Rs. 5/- each) (not annualised): 17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.)	17.26	17.11	11.73	56.20		ns, s) carry (not annuansed); ic (Rs.)	3	100	
19 ii Earnings per share (after extraordinary items) (of Rs. 5/- each) (not annualised): 17.11 11.73 56.20 a Basic (Rs.) 27.14 16.95	17.26	17.11	11.73	56.20		ited (Rs.)	27.14	16.95	e 2
17.11 11.73 56.20 a Basic (Rs.) 17.11 11.73 56.20 b Diluted (Rs.) 27.14 16.95					=:	nings per share (after extraordinary items)			Ç
17.11 11.73 56.20 b Diluted (Rs.)	17.26	17.11	11.73	56.20		RS. 5/- each) (not annualised): ir (pc)			
	17.26	17.11	11.73	56.20		re (PS.)	27.14	16.95	9.64

Notes :									
Ξ	The above result	s for the quarter	ended on June 3	0, 2015 w	The above results for the quarter ended on June 30, 2015 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on August 12, 2015.				
	The Statutory Au	ditors of the Com	pany have carrie	ed out a "t	The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per clause 41 of the Listing Agreement.				
<u>_</u>	In consolidated i	esuits, omer oper	ating income ro	the quan	in consolidated results, orner operating income for the quarter ended June 30, 2015 includes consideration of Rs. 6,666 Lacs [USD 10.5 Millions] received by Zydus Pharmaceuticals (USA) Inc., in consolidated results, other operating income for the quarter ended June 30, 2015 includes consideration of Rs. 6,666 Lacs [USD 10.5 Millions] received by Zydus Pharmaceuticals (USA) Inc., in consolidated results, other operating income for the quarter ended June 30, 2015 includes consideration of Rs. 6,666 Lacs [USD 10.5 Millions] received by Zydus Pharmaceuticals (USA) Inc., in consolidated results, other operating income for the quarter ended June 30, 2015 includes consideration of Rs. 6,666 Lacs [USD 10.5 Millions] received by Zydus Pharmaceuticals (USA) Inc., in consolidated results, other operating income for the quarter ended June 30, 2015 includes consideration of Rs. 6,666 Lacs [USD 10.5 Millions] received by Zydus Pharmaceuticals (USA) Inc., in consolidated results, other operating income for the quarter ended June 30, 2015 includes consideration of Rs. 6,666 Lacs [USD 10.5 Millions] received by Zydus Pharmaceuticals (USA) Inc., in consolidated results, other operations are also as a consolidated results of the cons	īć.,			
[4]	a wholly owned : Exceptional item:	a wholly owned subsidiary company, on sale and trail exceptional items in the consolidated results include:	ny, on sale and t ted results includ	ransfer of le:	a wholly owned subsidiary company, on sale and transfer of ownership interest in certain Abbreviated New Drug Applications [ANDAs] for generic drug products. Exceptional items in the consolidated results include:				
							Rupees in Lacs Corresp 3 mc	In Lacs Corresponding 3 months	:
	N _O				Particulars	3 Months ended 30/06/2015 (Unaudited)	Preceding 3 months ended 31/03/2015 (Audited)	<u> </u>	Previous year ended 31/03/2015 (Audited)
		Provision for varie	ous expenses rei	ated to the	Provision for various expenses related to the closure of business operations in Japan	0	(143)	118	
	n Er	Provision for amount payable to a former supplier for Payment made under Voluntary Retirement Scheme	unt payable to a ider Voluntary R	former su	Provision for amount payable to a former supplier for termination of supply contract, pursuant to the order passed by the Honfable High Court of Madrid, Spain Payment made under Voluntary Retirement Scheme	711) c		1,070
<u>5</u>	During the quart	er, the Company	has changed the	initial invo	During the quarter, the Company has changed the initial invoicing policy for supply of its products to its subsidiary companies. Consequently, there is a one-time impact on consolidated tax			9	
	expense for the	quarter ended Jur	ne 30, 2015, whi	ch is highe	expense for the quarter ended June 30, 2015, which is higher by Rs. 6,154 Lacs, though it has no impact on consolidated gross sales and profit before tax.				
<u> </u>	Figures of previo	Figures of previous reporting periods have been regrouped/ recla	ods have been re	grouped/	Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.				
r s		9							
	6				Select information for the Quarter Ended 30/06/2015				
		Corresponding 3 months ended						Corresponding 3 months	
3 Months ended 30/06/2015	Preceding 3 months ended 31/03/2015	30/06/2014 in the previous	Previous year ended 31/03/2015		Particulars	3 Months ended	Preceding 3 months ended	l4 in	Previous year ended
				>	PARTICULARS OF SHAREHOLDING	30,00,2020	21/03/2013	<u>a</u>	01/03/2013
	51 510 474			-	Public shareholding				
51,610,4/4	51,610,4/4	51,610,474	51,610,4/4		Number of shares	51,610,474	51,610,474	51,610,474	51,610,474
25.21%	25.21%	25.21%	25.21%	2	- Percentage of Shareholding Promoters and Promoter Group Shareholding	25.21%	25.21%	25.21%	25.21%
				a)	Pledged / Encumbered				
Z.	<u>z</u>	<u>z</u>	₹.		Number of shares	Z	<u>z</u>	<u>~</u>	
N.A.	N.A.	N.A.	N.A.		Percentage of shares (as a % of the total shareholding of promoter and promoter group)	N.A.	N.A.	Z Þ	
N.A.	N.A.	N.A.	A.N		Percentage of shares (as a % of the total share capital of the company)	N.A	N.A	N.A.	
				Б	Non - encumbered				
153,138,046	153,138,046	153,138,046	153,138,046		Number of shares	153,138,046	153,138,046	153,138,046	153,138,046
100.00%	100.00%	100.00%	100.00%		Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%
74.79%	74.79%	74.79%	74.79%			74.79%	74.79%	74.79%	74.79%
			·		Particulars	3 months ended 30/06/2015			
				Œ	INVESTOR COMPLAINTS [In Numbers]				
					Pending at the beginning of the quarter	Z.			
					Received during the quarter	6			
					Disposed of during the quarter	6			
					Remaining unresolved at the end of the quarter	Z.			

By Order of the Board,
For Cadila Healthcare Limited,
For Cadila Healthcare Limited,
Pankaj R. Patel
Chairman & Managing Director

Ahmedabad, August 12, 2015